Rivoceranib

Generic Name: Rivoceranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃N_₅O

CAS Number: 811803-05-1

Unique Ingredient Identifier: 5S371K6132

Background: Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication: 本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Apatinib Treatment for Advanced Esophagus Cancer

Phase 2

Conditions: Advanced Esophagus Cancer

Interventions: Drug: Apatinib

First Posted Date: 2017-05-31

Last Posted Date: 2017-05-31

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT03170310

Locations: 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China

APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC

Phase 2

Withdrawn

Conditions: Lung Cancer

Interventions: Drug: Apatinib
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2017-05-24

Last Posted Date: 2024-12-10

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 128

Registration Number: NCT03164694

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

Phase 2

Conditions: Osteosarcoma, Advanced

Interventions: Drug: Apatinib

First Posted Date: 2017-05-23

Last Posted Date: 2017-05-23

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT03163381

Locations: 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China

Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

Phase 2

Conditions: Biliary Tract Cancer

Interventions: Drug: Apatinib

First Posted Date: 2017-05-09

Last Posted Date: 2017-05-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 39

Registration Number: NCT03144856

Locations: 🇨🇳
Foshan people's Hospital, Foshan, Guangdong, China
🇨🇳
Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China

Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.

Phase 2

Conditions: Gastric Cancer

Interventions: Drug: Placebos
Drug: Apatinib

First Posted Date: 2017-05-09

Last Posted Date: 2017-05-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 110

Registration Number: NCT03144843

Locations: 🇨🇳
Foshan people's Hospital, Foshan, Guangdong, China
🇨🇳
Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China

The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer

Phase 2

Conditions: Apatinib in Maintenance Treatment

Interventions: Drug: Apatinib

First Posted Date: 2017-04-26

Last Posted Date: 2017-04-28

Lead Sponsor: Junling Li

Target Recruit Count: 52

Registration Number: NCT03129698

Locations: 🇨🇳
Junling Li, Beijing, Beijing, China

Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Phase 2

Conditions: Soft Tissue Sarcoma, Adult, Stage II

Interventions: Drug: Apatinib

First Posted Date: 2017-04-20

Last Posted Date: 2017-05-22

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 80

Registration Number: NCT03121846

Locations: 🇨🇳
Tianjin Medical University Cancer Hospital & Institute, Tianjin, Tianjin, China

Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Phase 2

Conditions: Metastatic Gastric Adenocarcinoma

Interventions: Drug: Apatinib
Drug: Irinotecan

First Posted Date: 2017-04-17

Last Posted Date: 2019-11-13

Lead Sponsor: China Medical University, China

Target Recruit Count: 37

Registration Number: NCT03116555

Locations: 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China

Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma

Phase 2

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Capecitabine
Drug: Apatinib

First Posted Date: 2017-04-14

Last Posted Date: 2017-05-15

Lead Sponsor: First Affiliated Hospital of Guangxi Medical University

Target Recruit Count: 170

Registration Number: NCT03114085

Apatinib for the Elderly Advanced Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: Apatinib

First Posted Date: 2017-04-07

Last Posted Date: 2022-03-15

Lead Sponsor: Affiliated Hospital of Qinghai University

Target Recruit Count: 48

Registration Number: NCT03104283

Locations: 🇨🇳
Qinghai Red Cross Hospital, Xining, Qinghai, China
🇨🇳
the Fifth People's Hospital of Qinghai Province, Xining, Qinghai, China
🇨🇳
Affiliated Hospital of Qinghai University, Xining, Qinghai, China

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy